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Trends in osteoporosis and mean 
bone density among type 2 
diabetes patients in the US 
from 2005 to 2014
Yingke Xu1,2 & Qing Wu 1,2*
This study aimed to examine how bone health changed among T2DM patients in the past decade. 
Continuous National Health and Nutrition Examination Survey (NHANES) data from 2005–2006 to 
2013–2014 were analyzed to examine the trends of bone mineral density (BMD) and the prevalence 
trends of osteoporosis osteopenia among T2DM patients and non-diabetic people aged 40 years and 
older. The age- and BMI-adjusted mean BMD of the femur neck for the four NHANES cycles decreased 
linearly in both T2DM patients and non-diabetic people (both  Plinear trend ≤ 0.009). Among women 
with T2DM, the mean BMD in 2013–2014 was significantly lower than that in 2005–2006, even after 
adjusting for multiple covariates. During 2005–2014, the prevalence of osteoporosis among T2DM 
patients and non-diabetic people increased but with no significant linear trend (both  Plinear trend > 0.05), 
while the prevalence of osteopenia in the two populations increased linearly (both  Plinear trend < 0.04). 
Age- and BMI-adjusted mean BMD decreased in 2013–2014 in patients with T2DM and non-diabetic 
people, while the prevalence of osteoporosis and osteopenia increased in both groups.
Osteoporosis and low bone mass (osteopenia) affect approximately 200 million people across the  world1, includ-
ing 54 million people in the United  States2. People with these conditions are prone to have fractures. Indeed, 
around 158 million people were at a high fracture risk in 2010, with that number predicted to double by  20143. 
These related fractures will ultimately lead to many issues in those afflicted, including movement restriction, 
disability, and severe morbidity.
Diabetes is characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or 
 both4,5. The number of people with diabetes worldwide has risen from 108 million in 1980 to 422 million in 
 20146. Even more notably, type 2 diabetes mellitus (T2DM) accounts for 90–95% of all  diabetes7. The prevalence 
of diabetes increased rapidly from 4.4 to 10.0% in the US between 1996 and  20158, and more than 30 million 
suffer from  T2DM9.
Osteoporosis and T2DM are affected by aging and often coexist in the  elderly10. T2DM affects bone metabo-
lism and strength by influencing osteoblast and  osteoclast11. The imbalance between osteoblast and osteoclast 
might cause  osteoporosis11. As well, T2DM might affect bone quality and quantity, leading to a change in the 
structural properties of bone  mass12. T2DM affects bone homeostasis, so related fractures are considered a 
result of  T2DM12,13. Several studies have already reported an increased fracture risk among T2DM  patients14–17. 
Therefore, evaluating the bone health of individuals with T2DM is essential in preventing osteoporosis and 
related fractures. However, to our knowledge, how the bone health of T2DM patients changed in recent years 
remains unclear. As BMD is the most important single predictor for osteoporotic fractures, the dual-energy 
X-ray absorptiometry (DXA)-based BMD has been the benchmark technique used in osteoporosis  diagnosis18,19. 
DXA-based BMD plays a crucial role in osteoporosis/osteopenia management and fracture risk assessment. 
Therefore, the present study aimed to test whether people with T2DM have had an elevated or decreased BMD 
in the past decades and compare the results to non-diabetic people. We also examined the trends of osteoporosis 
and osteopenia prevalence in T2DM patients and non-diabetic people.
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Methods
Data source. Data were obtained from the continuous National Health and Nutrition Examination Survey 
(NHANES). The survey uses a complex, multistage probability design to select a nationally representative sample 
of non-institutionalized civilians in the US  population20. NHANES collects data through interviews and physi-
cal examination. The interview includes demographic, socioeconomic, dietary, and health-related questions, 
while the examination consists of medical, dental, and physiological measurements. From 2005–2006, the sur-
vey started measuring femur and spine BMD; however, the BMD was not measured for NHANES in 2011–2012. 
Therefore, only four cycles (2005–2006, 2007–2008, 2009–2010, and 2013–2014) were included for this study. 
Subjects younger than 40 years old were excluded since participants are more likely to develop T2DM if they are 
40 or  over21.
Human participants. NHANES study protocol was approved by the National Center for Health Statistics 
Research Ethics Review Board. Written informed consent was obtained for all adult participants. This secondary 
analysis was approved by the institutional review board at the University of Nevada, Las Vegas (#1004670). All 
research reported in this manuscript was performed in accordance with relevant guidelines/regulations.
Diabetes mellitus. Subjects who had a positive response to the question, “Have you ever been told by a 
doctor that you have diabetes?” were defined as having a diagnosed diabetes. Individuals who reported tak-
ing pills to lower blood sugar were classified as having a diagnosed T2DM as well. This classification method 
was  used22, and other study using NHANES data adopted this method as  well23. Among participants without 
diagnosed diabetes, individuals who had a hemoglobin A1c level of 6.5% or higher, or a fasting plasma glucose 
level of 126 mg/dL or higher, or a 2-h plasma glucose level of 200 mg/dL or  higher5, were all classified as having 
“undiagnosed diabetes.” Because we could not distinguish between type 1 and type 2 diabetes based on these lab 
results, all of the undiagnosed diabetes in this study was assumed to be T2DM since T2DM comprises the major-
ity (90–95%) of  diabetes7. Diagnosed T2DM and undiagnosed T2DM were combined as the T2DM group in this 
study. People were classified as non-diabetic if they did not have diagnosed or undiagnosed diabetes.
BMD measurement. Femur neck BMD and spine BMD were measured using a Hologic QDR-4500A fan-
beam densitometer during 2005–2010. Both BMDs were obtained with a Hologic Discovery model A densitom-
eter (Hologic, Inc., Bedford, MA, USA) in 2013–2014. During 2005–2010, Hologic Discovery v12.4 and APEX 
v3.0 were used for analyzing the femur and spine scans, respectively. APEX v4.0 was used for the analysis in 
the two regions in 2013–2014. In this study, we focused on analyzing the femur neck BMD primarily because 
BMD at the femur neck has the highest predictive value for hip fracture, and the hip is the site of highest clinical 
 relevance24. We used femur neck BMD over spine BMD in this study because of significant differences in BMD 
measures between using Discovery v12.4 during 2005–2010 and using APEX v4.0 in 2013–2014, with the excep-
tion of the femur  neck25. In NHANES, DXA scans were used for the BMD measurement since the system has 
a number of advantages, the primary being a consensus that BMD results can be interpreted using the World 
Health Organization T-score definition of osteoporosis, thus having a proven ability to predict fracture  risk26.
Definition for osteoporosis and osteopenia. In this study, the diagnosis of osteoporosis or osteopenia 
was based on T-score results. T-scores were calculated as  (BMDmeasured − mean  BMDreference)/SDreference. Osteopo-
rosis was defined as a T-score of BMD ≤  − 2.5, and osteopenia was defined as − 2.5 < T-score ≤ − 127. Consistent 
with the International Society for Clinical Densitometry’s corresponding guidelines, the reference group for 
calculating these scores for the femur neck consisted of 20–29 years old non-Hispanic Caucasian women from 
NHANES  III28. In our study, subjects who lacked valid BMD data were excluded.
Other variables. Age, sex, race/ethnicity, smoking status, physical activities, fracture history, and family 
history were ascertained by questionnaire. For the race/ethnicity groups, “Mexican American” and “Other His-
panic” were merged into a single group called “Hispanic,” and the remaining groups were “non-Hispanic White,” 
“non-Hispanic Black,” and “non-Hispanic other,” respectively. BMD-related variables, including body mass index 
(BMI), previous  fracture29,30, smoking  status31,32, physical  activity33,34, and family history of  osteoporosis35, were 
considered for analysis. BMI was derived from measured weight in kilograms, divided by the square of height 
in meters. Individuals who had suffered a broken or fractured hip, wrist, or spine were considered as having a 
previous fracture. Smoking status was categorized into smokers and non-smokers. Smokers were respondents 
who had smoked at least 100 cigarettes during their lifetime; otherwise, subjects were defined as non-smokers. 
Self-reported physical activity was categorized as “inactive” and “active.” Participants who were sedentary or only 
performed basic activities, which refers to light-intensity activities like standing and walking slowly, were con-
sidered to be inactive; otherwise, the individuals were classified as  active36. In the present study, the participants 
were defined as having a family history of osteoporosis if their parent(s) ever had the disease.
Statistical analysis. Sampling weights were utilized to account for unequal selection probabilities, nonre-
sponse, and non-coverage37. The age- and BMI-adjusted mean BMD at the femur neck, prevalence of osteopo-
rosis and osteopenia, and corresponding 95% confidence interval in every survey cycle for both T2DM patients 
and non-diabetic people were calculated based on weighted data. Standard errors, which were employed to cal-
culate 95% confidence intervals, were estimated using Taylor series linearization. The US 2000 Census was used 
as the standard population for age adjustment. Tests for linear trend over the four survey cycles were conducted 
using orthogonal contrast. Multiple linear regression was used to examine the BMD trend while holding other 
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variables constant. The standardized coefficient from linear regression was employed to examine each variable’s 
relative importance in the regression model for BMD prediction. The survey cycle was included as a categorical 
variable in the multiple linear regression in order to determine if the mean BMD in 2013–2014 differed from 
previous survey cycles after adjusting for major confounders. We also conducted separate sensitivity analyses 
to examine the mean BMD trends across the four survey cycles in T2DM patients and non-diabetic population 
after adjusting for age and weight (instead of BMI) and in diagnosed and undiagnosed T2DM patients after 
adjusting for age and BMI. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA).
Results
The number of eligible participants in this study was 11,901, and their characteristics by survey cycles are 
presented in Table 1. During the four survey cycles, the mean age was around 62 years for T2MD patients and 
56 years for the non-diabetic population. From 2005 to 2014 mean BMI increased among T2DM patients (from 
29.93 to 31.38 kg/m2), as well as among the non-diabetic population (from 27.75 to 28.27 kg/m2). In each survey 
cycle, more than half of T2DM patients were men, while most non-diabetic participants were women. Over the 
four survey cycles, the percentage of physical inactivity increased from 14.04 to 34.61% in T2DM patients and 
from 9.89 to 23.80% in the non-diabetic population.
Adjusted mean femur neck BMD. The age- and BMI-adjusted mean BMD of T2DM patients and non-
diabetic people in the four survey cycles are shown in Fig. 1a. For T2DM patients, the mean BMD decreased 
linearly from 0.813 g/cm2 (95% CI 0.796–0.829 g/cm2) to 0.784 g/cm2 (95% CI 0.771–0.796 g/cm2) during 2005–
2014  (Plinear trend = 0.004). Meanwhile, the mean BMD of non-diabetic also decreased linearly during the four 
survey cycles  (Plinear trend = 0.0009), from 0.795 to 0.773 g/cm2.
The results of age- and BMI- adjusted mean BMD of T2DM patients stratified by gender are presented in 
Fig. 1b. Among patients with T2DM, women had a lower mean BMD than men during the four survey cycles. 
In 2005–2014, the mean BMD of women with T2DM linearly decreased  (Plinear trend = 0.007), but no significant 
linear trend  (Plinear trend = 0.1) was observed among men with T2DM.
The age- and BMI-adjusted mean BMD of the non-diabetic population stratified by gender are presented 
in Supplementary Figure 1. Significant linear trends were observed for both genders during 2005–2014 (both 
 Plinear trend ≤ 0.005). Our sensitivity analysis revealed that the results of age- and weight-adjusted mean BMD (Sup-
plementary Figure 2) were similar to age- and BMI-adjusted mean BMD. In addition, the age- and BMI-adjusted 
mean BMD (Supplementary Figure 3) decreased linearly in people with diagnosed T2DM (P linear trend = 0.02), but 
not for people with undiagnosed T2DM  (Plinear trend = 0.39) during 2005–2014.
Prevalence of osteoporosis and osteopenia. The age- and BMI-adjusted prevalence of osteoporosis 
and osteopenia of T2DM patients and non-diabetic people from 2005 to 2014 are presented in Table 2. The 
adjusted prevalence of osteoporosis among T2DM patients increased from 3.13% (95% CI 1.39–4.87%) to 
6.10% (95% CI 4.47–7.75%) during 2005–2014, and the linear trend was close to being statistically significant 
Table 1.  Weighted characteristics of subjects aged 40 and older, among T2DM patients and non-diabetic 
population in 4 NHANES (2005–2006, 2007–2008, 2009–2010, and 2013–2014).
Variable
Survey cycle

















Age, mean (SD), 
years 62.12 ± 0.85 55.51 ± 0.71 61.47 ± 0.51 55.60 ± 0.32 62.47 ± 0.72 55.84 ± 0.39 61.22 ± 0.71 56.42 ± 0.34
BMI, mean (SD), 
kg/m2 29.93 ± 0.30 27.75 ± 0.21 31.32 ± 0.29 27.74 ± 0.12 31.23 ± 0.27 27.86 ± 0.14 31.38 ± 0.26 28.27 ± 0.19
Gender, N (%)
Men 227 (53.26) 975(48.53) 394 (51.87) 1209 (46.39) 377 (52.12) 1323 (48.08) 371 (57.04) 1162 (47.81)
Women 182 (46.74) 878 (51.47) 326 (48.13) 1256 (53.61) 357 (47.88) 1296 (51.92) 303 (42.96) 1265 (52.19)
Race, N (%)
Hispanic 115 (13.33) 323 (7.05) 208 (11.92) 617 (9.21) 260 (15.67) 678 (9.76) 192 (16.44) 496 (10.26)
NH White 166 (66.58) 1108 (80.19) 316 (67.67) 1315 (76.36) 293 (64.45) 1411 (76.17) 234 (61.41) 1132 (73.44)
NH Black 112 (14.60) 356 (8.13) 174 (14.47) 437 (8.75) 134 (12.04) 418 (8.77) 156 (13.26) 462 (9.38)
NH other 16 (5.49) 66 (4.63) 22 (5.94) 96 (5.68) 47 (7.84) 112 (5.29) 92 (8.88) 337 (6.92)
Previous fracture, 
N (%) 55 (15.79) 272 (14.97) 89 (13.76) 328 (14.49) 74 (11.22) 306 (12.02) 73(12.80) 260 (12.34)
Smoking, N (%) 226(52.20) 995 (53.61) 380 (52.21) 1245 (48.77) 362 (49.04) 1287 (46.54) 326 (50.96) 1111(45.30)
Physical inactivity, 




28 (10.17) 213 (14.29) 67 (12.71) 334 (16.74) 61 (8.97) 292 (14.47) 74 (13.51) 312 (16.84)
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Figure 1.  Age and body mass index-adjusted mean bone mineral density in 4 NHANES (2005–2006, 2007–
2008, 2009–2010, and 2013–2014).
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 (Plinear trend = 0.054). For non-diabetic individuals, the adjusted prevalence of osteoporosis was stable during this 
period  (Plinear trend = 0.35). The adjusted osteopenia prevalence of T2DM patients and non-diabetic people had a 
significant increase in the linear trend (both  Plinear trend ≤ 0.04).
The age- and BMI-adjusted prevalence of osteoporosis and osteopenia among T2DM patients by gender are 
presented in Table 3. The linear trend of the osteoporosis prevalence among women approached the borderline 
of significance  (Plinear trend = 0.08) but was non-significant for men  (Plinear trend = 0.14). The osteoporosis prevalence 
among women with T2DM increased from 3.95% (95% CI 0–7.98%) to 10.13% (95% CI 6.06–14.21%) during 
the four survey cycles. For the prevalence of osteopenia among T2DM patients, a significant increase in linearly 
trend was observed in women  (Plinear trend = 0.04), but not in men  (Plinear trend = 0.35). The prevalence of osteopo-
rosis and osteopenia in non-diabetic people by gender is presented in Supplementary Table 1. The prevalence of 
osteoporosis in non-diabetic men and women was stable during the four survey cycles (both  Plinear trend > 0.29). 
However, significant linear trends in osteopenia prevalence were observed in non-diabetic men and women 
during the four survey cycles (both  Plinear trend  ≤  0.004).
Multiple linear regression. For women with T2DM, older age and previous fractures were significantly 
associated with decreased BMD, based on the multiple linear regression (both p ≤ 0.03; Supplementary Table 2). 
For men with T2DM, older age, family history of osteoporosis, physical inactivity, and smoking were associated 
with significant BMD reduction (all p < 0.007; Supplementary Table 3). The standardized coefficient revealed 
that age played a more critical role than other risk factors in lowering BMD for T2DM patients of both sexes. The 
selected covariates explained around 35% variance of BMD at the femur neck in women and about 27% in men. 
The mean BMD of women with T2DM in 2013–2014 was significantly lower than in 2005–2006 (p = 0.0007; 
Supplementary Table 2), even after adjusting for various confounders. The results of non-diabetic individuals, 
both women and men, are respectively presented in Supplementary Table 4 and Table 5. For non-diabetic people, 
a family history of osteoporosis, age, and physical inactivity had a significant negative impact on BMD in both 
men and women.
Discussion
In this study, decreasing BMD trends at the femur neck were observed among T2DM patients and non-diabetic 
people during 2005–2014. In addition, the prevalence of osteoporosis and osteopenia among subjects with 
T2DM increased correspondingly in the four survey cycles. Specifically, a significant increasing linear trend 
in the prevalence of osteoporosis and osteopenia was observed among women with T2DM. These consistent 
results demonstrate that an unfavorable trend of change in bone health in T2DM patients may be occurring in 
the United States.
Compared to our prior study regarding the US BMD trend in 2005–201438, the present research further exam-
ined the BMD trend, osteoporosis, and osteopenia in the US’s T2DM population. There is a paucity of research 
investigating the BMD trend and the pattern of osteoporosis and osteopenia in T2DM patients, specifically a lack 
Table 2.  Age- and BMI-adjusted prevalence of osteoporosis and osteopenia among T2DM patients and non-
diabetic population in 4 NHANES (2005–2006, 2007–2008, 2009–2010, and 2013–2014).
Prevalence
Survey cycle
2005–2006 2007–2008 2009–2010 2013–2014 P value for linear trend
Osteoporosis
T2DM 3.13 (1.39–4.87) 4.50 (1.55–7.44) 3.10 (1.75–4.44) 6.10 (4.47–7.75) 0.054
Non diabetic 4.03 (3.26–4.79) 3.03 (2.30–3.74) 3.81 (3.18–4.46) 4.38 (3.39–5.37) 0.35
Osteopenia
T2DM 27.83 (21.62–34.03) 31.14 (26.75–35.54) 32.56 (27.15–37.97) 35.49 (30.06–40.92) 0.04
Non diabetic 32.23 (29.81–34.64) 30.27 (28.14–32.41) 32.82 (30.81–34.84) 38.20 (35.51–40.90) 0.0005
Table 3.  Age- and BMI-adjusted prevalence of osteoporosis and osteopenia among T2DM patients stratified 
by gender in 4 NHANES (2005–2006, 2007–2008, 2009–2010, and 2013–2014).
Prevalence
Survey cycle
2005–2006 2007–2008 2009–2010 2013–2014 P value for linear trend
Osteoporosis
Men 0.02 (0–0.30) 2.29 (0–4.87) 1.31 (0–2.63) 1.21 (0.42–2.00) 0.14
Women 3.95 (0–7.98) 4.95 (1.67–8.23) 3.19 (0.81–5.57) 10.13 (6.06–14.21) 0.08
Osteopenia
Men 21.34 (14.34–28.34) 22.44 (18.05–26.82) 20.98 (14.68–27.28) 27.14 (19.01–35.26) 0.35
Women 25.22 (18.82–31.62) 31.13 (25.08–37.17) 35.34 (27.52–43.15) 35.42 (26.82–44.02) 0.04
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of data comparing the trend between individuals with T2DM and those without diabetes. In this study, T2DM 
patients had a higher BMD than non-diabetic people, consistent with Dr. Oei et al.’s  research16,39. Among T2DM 
patients, men had a higher BMD mean than women. The possible reason for this is that men have a larger bone 
mass than  women40. Notably, the mean BMD in 2013–2014 among women with T2DM was significantly lower 
than the mean BMD in 2005–2006. Such a difference remained when adjusted for multiple related factors, imply-
ing proper intervention might be needed. Although such a linear trend of BMD was not observed among men 
in the current study, attention should be paid to men since a previous study showed that men with diabetes had 
a higher risk of  fracture41. Our findings of non-diabetic people were consistent with a recent study conducted 
by Dr. Chi Chen et al. that found a declining BMD trend among adults with normal glucose  regulation42. The 
decreasing mean BMD trend of this study demonstrates that the bone health of T2DM patients and non-diabetic 
people might have deteriorated significantly in recent years. In Dr. Black and colleagues’  study43, people with the 
lowest quartile of BMD almost had fivefold increased hip fracture risk during 25 years follow-up when compared 
with those with the highest quartile of BMD. Therefore, as shown in the current study, primary prevention and 
treatment should be conducted among the non-diabetic population with the lowest quartile BMD.
The multiple linear regression results indicated that sex, age, race, previous fracture, BMI, smoking, and 
physical activity are significant for T2DM  patients6,8,27,29–35,44–48. Thus these related risk factors might partially 
contribute to the declining trend in mean BMD. The percentage of physical inactivity increased from 14.04 to 
34.61% among T2DM and from 9.89 to 23.80% among non-diabetics. Given the association between physical 
inactivity and lower  BMD34, the increased physically inactive lifestyle might also explain the decreasing BMD 
trends occurring during the four survey cycles. However, the decreased BMD in 2013–2014 among women with 
T2DM remained significant after controlling for major confounding effects in the multiple regression analysis. 
Thus other factors such as antidiabetic medication of T2DM patients may play a role in the observed  trend49,50. 
For example, Dr. Monami and colleagues found an increased risk of fracture among T2DM patients who used 
 insulin51. Patients with insulin usually have complications such as microvascular disease, which might impair 
the bone quality and individual  balance52, thus increasing fracture risk. Additionally, Schwartz et al. reported an 
increased bone loss in diabetic women who had taken thiazolidinediones medication (TZD), including rosigli-
tazone, pioglitazone, and  troglitazone49. Several studies investigated the effect of TZD on bone metabolism and 
found it is associated with increased adipogenesis and impaired osteoblastogenesis, which might lead to impaired 
bone formation and ultimately to  fractures53. Other studies found that two medications, exenatide (a glucagon-
like peptide 1 receptor agonist) and dapagliflozin (a sodium glucose cotransporter-2 inhibitor) increased the risk 
of bone  fractures54,55, while dipeptidyl peptidase-4 inhibitors were associated with decreased fracture  risk26,54,56. 
Further research is warranted to explain the overall declining BMD trend in T2DM patients.
The underlying pathogenic mechanism of bone fragility in T2DM is complex and not fully  understood12. Not 
only decreased bone mass but also bone microstructure might contribute to bone fracture. Typically, increased 
cortical porosity and reduced cortical density lead to bone structure  change52. Prior studies found that T2DM 
patients had greater cortical  porosity57,58, but lower cortical bone  density59. Therefore, bone resistance to mechani-
cal stress among T2DM patients will be increased, which will result in an increased risk of fracture.
Several limitations should be acknowledged in interpreting the finding of this study. First, many of the 
NHANES participants were excluded from BMD measurement due to hip fractures, pregnancy, or other reasons. 
However, nonresponse in the examination data was accounted for by sampling weights in NHANES. Second, 
information about T2DM treatment, which might impact bone health, is limited in NHANES. For example, TZD 
is widely prescribed for the treatment of T2DM, and accumulating evidence indicates that TZD could cause bone 
loss and increase fracture risk in humans, specifically in  women49. However, too few participants reported this 
information, so we cannot analyze it to yield valid results. Third, the evaluation of the trend in hemoglobin A1c 
among T2DM patients would be informative since several studies reported the association between poor glycemic 
control and increased risk of  fractures60–63. However, the missing value of hemoglobin A1c from NHANES is 
too much (around 80%) to get an accurate evaluation. Finally, the study design of NHANES is cross-sectional, 
which restricts the assessment of causal relationships.
Osteoporosis and low BMD lead to fractures, which cause severe consequences for both individual patients 
and health care  systems24. Osteoporosis-related fractures often lead to decreased quality of life, disability, and 
even death for patients and are also associated with $20 billion in expenses in the  US64. Due to T2DM patients 
having normal or higher BMD, BMD-based T-score might underestimate the fracture risk of T2DM patients, 
and evaluation of bone health and osteoporosis diagnosis among them might be  challenging52. Derived from 
continuous NHANES data, our findings regarding osteoporosis trends and mean BMD among T2DM patients 
can be used to inform public health policy and thus contribute to needed reform. Policy intervention may help 
to reduce risk factors associated with the downward trend of bone health inT2DM patients.
Conclusion
In summary, a decreasing age- and BMI-adjusted mean BMD trend has been observed in T2DM patients and 
the non-diabetic population in recent years. The unfavorable trend indicates a future downward shift in the bone 
health of T2DM patients, so bone health should be monitored in diabetic patients. Therefore, additional stud-
ies are warranted to understand the decreasing BMD trend among T2DM patients more thoroughly to prevent 
fractures and their subsequent deleterious consequences on individuals with diabetes.
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